Moleculin Biotech マネジメント

マネジメント基準チェック /34

Moleculin Biotechの CEO はWally Klempで、 Jul2015年に任命され、の在任期間は 9.33年です。の年間総報酬は$ 1.41Mで、 39.9%給与と60.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.56%を直接所有しており、その価値は$ 210.13K 。経営陣と取締役会の平均在任期間はそれぞれ7.1年と5.7年です。

主要情報

Wally Klemp

最高経営責任者

US$1.4m

報酬総額

CEO給与比率	39.9%
CEO在任期間	9.3yrs
CEOの所有権	2.6%
経営陣の平均在職期間	7.1yrs
取締役会の平均在任期間	5.7yrs

経営陣の近況

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

CEO報酬分析

Moleculin Biotech の収益と比較して、Wally Klemp の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$1m	US$565k	-US$30m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$2m	US$565k	-US$29m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$18m
Dec 31 2021	US$2m	US$538k	-US$16m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$2m	US$500k	-US$17m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$2m	US$625k	-US$13m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$403k	-US$12m
Sep 30 2018	n/a	n/a	-US$12m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$1m	US$325k	-US$10m

報酬と市場: Wallyの総報酬 ($USD 1.41M ) は、 US市場 ($USD 649.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Wallyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Wally Klemp (64 yo)

9.3yrs

在職期間

US$1,414,599

報酬

Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He Co-Founded Moleculin Biotech, Inc. in July 2015 and has been its Chief...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Walter Klemp	Co-Founder	9.3yrs	US$1.41m	2.56% $ 210.1k
Jonathan Foster	Executive VP & CFO	8.3yrs	US$840.64k	0.40% $ 32.7k
Donald Picker	Chief Scientific Officer	7.3yrs	US$599.11k	0.28% $ 23.1k
Waldemar Priebe	Co-Founder	no data	データなし	データなし
John Waymack	Senior Chief Medical Officer	3.1yrs	データなし	データなし
Sandra Silberman	Chief Medical Officer of New Products	7yrs	データなし	データなし
Wolfram C. Dempke	European Chief Medical Officer	2.5yrs	データなし	データなし

7.1yrs

平均在職期間

69yo

平均年齢

経験豊富な経営陣: MBRXの経営陣は経験豊富で経験豊富です（平均在職期間は7.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Walter Klemp	Co-Founder	9.3yrs	US$1.41m	2.56% $ 210.1k
Waldemar Priebe	Co-Founder	no data	データなし	データなし
Michael Cannon	Independent Director	8.4yrs	US$68.52k	0% $ 0
Daniel Von Hoff	Member of Scientific Advisory Board	no data	データなし	データなし
John Climaco	Lead Independent Director	7.3yrs	US$81.05k	0% $ 0
Elizabeth Cermak	Independent Director	4.1yrs	US$63.52k	0% $ 0
Martin Tallman	Member of Annamycin Scientific Advisory Board	less than a year	データなし	データなし
Robert George	Independent Director	8.4yrs	US$74.90k	0.034% $ 2.8k
Joy Yan	Independent Director	2.7yrs	US$47.15k	0% $ 0

5.7yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: MBRXの取締役会は経験豊富であると考えられます ( 5.7年の平均在任期間)。

Moleculin Biotech マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Recent updates

New major risk - Shareholder dilution

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

New minor risk - Profitability

New major risk - Financial position

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

マネジメント基準チェック /34